Lipoprotein Lipase LPL Polymorphism and the Risk of Coronary Artery Disease: A Meta-AnalysisReport as inadecuate


Lipoprotein Lipase LPL Polymorphism and the Risk of Coronary Artery Disease: A Meta-Analysis


Lipoprotein Lipase LPL Polymorphism and the Risk of Coronary Artery Disease: A Meta-Analysis - Download this document for free, or read online. Document in PDF available to download.

Department of Cardiovascular Medicine, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China



These authors contributed equally to this study.





*

Author to whom correspondence should be addressed.



Academic Editor: Peter Clifton

Abstract Background: In recent years, the lipoprotein lipase LPL polymorphism has been extensively investigated as a potential risk factor for coronary artery disease CAD. However, the results of these studies have been inconsistent. Therefore, we performed this meta-analysis to explore the association between LPL polymorphism and CAD risk. Methods: The literature was searched from electronic databases such as Embase, China Biological Medicine Database, PubMed, Knowledge Infrastructure, and China National Web of Science by the key words -coronary artery disease- -lipoprotein lipase- and -polymorphism-. All of the studies included in this manuscript met the inclusion and exclusion criteria. An odds ratio OR analysis using a 95% confidence interval CI was employed to assess the association of the LPL polymorphism with CAD susceptibility. Results: We performed a meta-analysis of 14 case-control studies including HindIII, Ser447X and PvuII polymorphism. A statistically significant increase in the risk of CAD was associated with LPL HindIII polymorphism. This included HindIII H+H+ genotype OR = 1.28, 95% CI = 1.09–1.49, p = 0.002, I2 = 43% and H+ allele genotype OR = 1.27, 95% CI = 1.03–1.58, p = 0.03, I2 = 67%. Ser447X XX genotype OR = 2.37, 95% CI = 1.33–4.24, p = 0.004, I2 = 53% was also associated with CAD risk. However, PvuII polymorphism was found to have no significant association with CAD risk. Conclusions: LPL HindIII polymorphism was significantly associated with the risk of CAD. For Ser447X polymorphism, it was found that only XX genotype was significantly associated with CAD risk. Furthermore, PvuII polymorphism had no significant association with CAD risk. It was considered that LPL HindIII polymorphism might serve as a potential biomarker for CAD risk. View Full-Text

Keywords: coronary artery disease; lipoprotein lipase; polymorphism; meta-analysis coronary artery disease; lipoprotein lipase; polymorphism; meta-analysis





Author: Li Xie †,* and You-Mei Li †

Source: http://mdpi.com/



DOWNLOAD PDF




Related documents